Monday, September 21, 2020 8:22:20 AM
Recent XERS News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 08:19:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:15:27 PM
- Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024 • Business Wire • 06/03/2024 11:00:00 AM
- Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121) • Business Wire • 05/30/2024 11:30:00 AM
- Xeris to Participate in the Jefferies Global Healthcare Conference • Business Wire • 05/30/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:14:33 AM
- Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events • Business Wire • 05/09/2024 11:00:00 AM
- Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics • Business Wire • 05/06/2024 11:00:00 AM
- Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024 • Business Wire • 05/02/2024 11:00:00 AM
- Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 04/03/2024 08:05:00 PM
- Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference • Business Wire • 04/02/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/06/2024 09:19:18 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 09:10:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 12:27:40 PM
- Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events • Business Wire • 03/06/2024 12:02:00 PM
- Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital • Business Wire • 03/06/2024 12:00:00 PM
- Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024 • Business Wire • 02/28/2024 12:00:00 PM
- Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference • Business Wire • 02/05/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 10:05:28 PM
- Xeris Biopharma Shares Climb 12% on Amgen License Agreement • Dow Jones News • 01/10/2024 03:12:00 PM
- Xeris Biopharma Reaches License Agreement With Amgen On Thyroid Eye Disease Treatment • Dow Jones News • 01/10/2024 01:53:00 PM
- Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab • Business Wire • 01/10/2024 01:00:00 PM
- Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 01/05/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 12:09:00 PM
- Xeris Biopharma Updates Its Outlook for 2023 • Business Wire • 01/04/2024 12:00:00 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM